{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:29:58Z","timestamp":1791422998633,"version":"4.3.3"},"reference-count":44,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction The Young Mania Rating Scale (YMRS) is the gold standard to\n                    assess manic symptoms of bipolar disorder, yet the clinical meaning of scores is\n                    unknown. To clinically understand and interpret YMRS scores, we examined\n                    linkages between the total and change scores of YMRS with the Clinical Global\n                    Impression (CGI) ratings.<\/jats:p><jats:p>\n          Methods Individual participant data (N=2,988) from eight\n                    randomized, double-blind, placebo-controlled trials were included. Data were\n                    collected at baseline and subsequent visits. Spearman\u2019s correlation\n                    coefficients \u03c1 were computed, and equipercentile linking was\n                    implemented.<\/jats:p><jats:p>\n          Results A YMRS score of 6 points corresponded approximately to\n                    \u2018borderline mentally ill,\u2019 12 points to \u2018mildly\n                    ill,\u2019 20 points to \u2018moderately ill,\u2019 30 points to\n                    \u2018markedly ill,\u2019 40 points to \u2018severely ill,\u2019 and\n                    52 points to \u2018among the most extremely ill\u2019 patients on the\n                    CGI-S. A reduction of CGI-S by one point as well as \u2018minimally\n                    improved\u2019 on the CGI-I corresponded approximately to an absolute\n                    decrease of 4 to 8 YMRS points or a 21% to 29% reduction of YMRS\n                    baseline score whereas a reduction of CGI-S by two points and \u2018much\n                    improved\u2019 on the CGI-I corresponded to an absolute decrease of 10 to 15\n                    points or a 42% to 53% reduction of YMRS baseline score.<\/jats:p><jats:p>\n          Discussion The current study findings offer clinicians meaningful cutoff\n                    values to interpret YMRS scores. Moreover, these values contribute to the\n                    definition of treatment targets, response, remission, and entry criteria in\n                    mania trials.<\/jats:p>","DOI":"10.1055\/a-1841-6672","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:42:47Z","timestamp":1658972567000},"page":"18-24","source":"Crossref","is-referenced-by-count":23,"title":["Linkage of Young Mania Rating Scale to Clinical Global Impression\n                    Scale to Enhance Utility in Clinical Practice and Research\n                    Trials"],"prefix":"10.1055","volume":"56","author":[{"given":"Myrto T.","family":"Samara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Thessaly,\n                    Larisa, Greece"},{"name":"Department of Psychiatry and Psychotherapy, Technical University of\n                    Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Z.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Community Mental Health, Faculty of Social Welfare and\n                    Health Sciences, University of Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of\n                    Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: Reliability, validity and sensitivity","volume":"133","author":"R C Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/cap.2007.0057","article-title":"Evaluation and comparison of psychometric instruments for pediatric bipolar\n                    spectrum disorders in four age groups","volume":"17","author":"T W Frazier","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1207\/S15374424JCCP3104_15","article-title":"Factor structure of the Young Mania Rating Scale for use with youths ages 5 to\n                    17 years","volume":"31","author":"E A Youngstrom","year":"2002","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/104454603321666162","article-title":"Methodological issues and controversies in clinical trials with child and\n                    adolescent patients with bipolar disorder: Report of a consensus conference","volume":"13","author":"G A Carlson","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1207\/s15374424jccp3403_4","article-title":"Toward an evidence-based assessment of pediatric bipolar disorder","volume":"34","author":"E A Youngstrom","year":"2005","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of 2 dose ranges of\n                    paliperidone extended-release in the treatment of subjects with schizoaffective\n                    disorder","volume":"71","author":"C M Canuso","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","article-title":"Paliperidone extended-release in schizoaffective disorder: a randomized,\n                    controlled study comparing a flexible dose with placebo in patients treated with\n                    and without antidepressants and\/or mood stabilizers","volume":"30","author":"C M Canuso","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jad.2016.06.062","article-title":"An item response theory evaluation of the young mania rating scale and the\n                    montgomery-asberg depression rating scale in the systematic treatment\n                    enhancement program for bipolar disorder (STEP-BD)","volume":"205","author":"J J Prisciandaro","year":"2016","journal-title":"J Affect Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpsychores.2009.05.003","article-title":"Assessment of mood: Guides for clinicians","volume":"68","author":"T A Furukawa","year":"2010","journal-title":"J Psychosom Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/chi.0b013e3180335ae4","article-title":"Response and remission in adolescent mania: signal detection analyses of the\n                    young mania rating scale","volume":"46","author":"N C Patel","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind,\n                    placebo-controlled study. The Olanzipine HGGW Study Group","volume":"57","author":"M Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mpr.1379","article-title":"Young Mania Rating Scale: How to interpret the numbers? Determination of a\n                    severity threshold and of the minimal clinically significant difference in the\n                    EMBLEM cohort","volume":"22","author":"M Lukasiewicz","year":"2013","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref13","first-page":"CD004048","article-title":"Lithium for acute mania","volume":"6","author":"R F McKnight","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2017.09.040","article-title":"Clinically relevant response and remission outcomes in cariprazine-treated\n                    patients with bipolar I disorder","volume":"226","author":"W Earley","year":"2018","journal-title":"J Affect Disord"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2007.08.015","article-title":"Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed\n                    episodes of bipolar I disorder","volume":"107","author":"T Suppes","year":"2008","journal-title":"J Affect Disord"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2014.06.039","article-title":"Efficacy of olanzapine in the treatment of bipolar mania with mixed features\n                    defined by DSM-5","volume":"168","author":"M Tohen","year":"2014","journal-title":"J Affect Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopsych.2005.03.019","article-title":"Open-label, 8-week trial of olanzapine and risperidone for the treatment of\n                    bipolar disorder in preschool-age children","volume":"58","author":"J Biederman","year":"2005","journal-title":"Biol Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","article-title":"A prospective open-label treatment trial of olanzapine monotherapy in children\n                    and adolescents with bipolar disorder","volume":"11","author":"J A Frazier","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jad.2007.06.011","article-title":"The empirical redefinition of the psychometric criteria for remission in bipolar\n                    disorder","volume":"106","author":"M Berk","year":"2008","journal-title":"J Affect Disord"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","article-title":"Evidence-based guidelines for interpretation of the Panic Disorder Severity\n                    Scale","volume":"26","author":"T A Furukawa","year":"2009","journal-title":"Depress Anxiety"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major\n                    depressive disorder, panic disorder, social anxiety disorder, and generalized\n                    anxiety disorder?","volume":"67","author":"B Bandelow","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S0033291703007414","article-title":"Evaluation of the clinical global impression scale among individuals with social\n                    anxiety disorder","volume":"33","author":"T I Zaider","year":"2003","journal-title":"Psychological medicine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3233\/JAD-201541","article-title":"Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician\u2019s\n                    Interview-Based Impression Plus caregiver input, and the Clinical Global\n                    Impression Scale: Evidence based on individual participant data from five\n                    randomized clinical trials of donepezil","volume":"82","author":"M Samara","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hup.2526","article-title":"Validation of the 17-item Hamilton Depression Rating Scale definition of\n                    response for adults with major depressive disorder using equipercentile linking\n                    to Clinical Global Impression scale ratings: analysis of Pharmacogenomic\n                    Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS)\n                    data","volume":"31","author":"W V Bobo","year":"2016","journal-title":"Hum Psychopharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jad.2016.12.041","article-title":"What does the MADRS mean? Equipercentile linking with the CGI using a company\n                    database of mirtazapine studies","volume":"210","author":"S Leucht","year":"2017","journal-title":"J Affect Disord"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: Clinical implications","volume":"31","author":"S Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: An examination of\n                    the PANSS and CGI","volume":"98","author":"S Z Levine","year":"2008","journal-title":"Schizophr Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.euroneuro.2014.08.009","article-title":"Equipercentile linking of scales measuring functioning and symptoms: Examining\n                    the GAF, SOFAS, CGI-S, and PANSS","volume":"24","author":"M T Samara","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.apmr.2016.04.001","article-title":"What to do with \u201cModerate\u201d reliability and validity\n                    coefficients?","volume":"97","author":"M W Post","year":"2016","journal-title":"Arch Phys Med Rehabil"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v074.i08","article-title":"equate: An R package for observed-score linking and equating","volume":"74","author":"A D Albano","year":"2016","journal-title":"J Stat Softw"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ebmental-2020-300240","article-title":"How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis\n                    of PHQ-9 and EQ-5D","volume":"24","author":"T A Furukawa","year":"2021","journal-title":"Evid Based Ment Health"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/ebmental-2020-300184","article-title":"Linking the Mini-Mental State Examination, the Alzheimer\u2019s Disease\n                    Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: Evidence\n                    from individual participant data from five randomised clinical trials of\n                    donepezil","volume":"24","author":"S Z Levine","year":"2021","journal-title":"Evid Based Ment Health"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jad.2010.06.030","article-title":"Evaluation of the efficacy and safety of paliperidone extended-release in the\n                    treatment of acute mania: A randomized, double-blind, dose-response study","volume":"136","author":"J Berwaerts","year":"2012","journal-title":"J Affect Disord"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-5618.2010.00815.x","article-title":"A randomized, placebo- and active-controlled study of paliperidone extended\n                    release for the treatment of acute manic and mixed episodes of bipolar I\n                    disorder","volume":"12","author":"E Vieta","year":"2010","journal-title":"Bipolar Disord"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with\n                    bipolar disorder: A randomized, double-blind, placebo-controlled study","volume":"11","author":"M Haas","year":"2009","journal-title":"Bipolar Disord"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-5618.2006.00276.x","article-title":"Topiramate monotherapy in the management of acute mania: Results of four\n                    double-blind placebo-controlled trials","volume":"8","author":"S F Kushner","year":"2006","journal-title":"Bipolar Disord"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","article-title":"Acute and continuation risperidone monotherapy in bipolar mania: A 3-week\n                    placebo-controlled trial followed by a 9-week double-blind trial of risperidone\n                    and haloperidol","volume":"15","author":"A B Smulevich","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"S Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"ref41","first-page":"7","article-title":"Defining the clinical course of bipolar disorder: response, remission, relapse,\n                    recurrence, and roughening","volume":"40","author":"R M Hirschfeld","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"ref42","first-page":"12","article-title":"Criteria for defining symptomatic and sustained remission in bipolar I disorder:\n                    A post-hoc analysis of a 26-week aripiprazole study (study CN138-010)","volume":"41","author":"P S Masand","year":"2008","journal-title":"Psychopharmacol Bull"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2018.11.014","article-title":"Generalizability of findings from randomized controlled trials is limited in the\n                    leading general medical journals","volume":"107","author":"A Malmivaara","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.ejim.2016.07.009","article-title":"Are we really tackling the \u201cevidence-based medicine issue\u201d in\n                    Alzheimer\u2019s disease?","volume":"35","author":"M Canevelli","year":"2016","journal-title":"Eur J Intern Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-1014401","article-title":"\u201cClinical Global Impressions\u201d (ECDEU): Some critical\n                    comments","volume":"25","author":"M Beneke","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"ref46","first-page":"327","article-title":"A comparison of symptom determinants of patient and clinician global ratings in\n                    patients with panic disorder and depression","volume":"13","author":"A C Leon","year":"1993","journal-title":"J Clin Psychopharmacol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1841-6672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:48:00Z","timestamp":1672876080000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1841-6672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":44,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1841-6672","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}